Literature DB >> 199222

Studies on brain metabolism of biogenic amines.

U Schacht, M Leven, G Bäcker.   

Abstract

1. In vitro models (synaptosones, electrically stimulated brain slices and monoamine oxidase (MAO) preparations have been used to identify the sites of action of nomifensine on brain monoamine metabolism. 2. Nomifensine potentiates neurotransmission in noradrenergic and dopaminergic synapses by blocking catecholamine uptake. 3. Nomifensine does not inhibit MAO and does not enhance the release of biogenic amines. 4. Studies on electrically stimulated brain slices suggest that nomifensine does not directly stimulate dopamine (DA) nor noradrenaline (NA) receptor sites. 5. 5-Hydroxytryptamine (5-HT) uptake is not inhibited at "therapeutic" concentrations of nomifensine. 6. Nomifensine differs from the tricyclic antidepressants by virtue of its effect on the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 199222      PMCID: PMC1429133          DOI: 10.1111/j.1365-2125.1977.tb05763.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

Review 1.  Presynaptic alpha-adrenoceptors.

Authors:  K Starke; T Endo
Journal:  Gen Pharmacol       Date:  1976-10

Review 2.  Biogenic amines and affective disorders.

Authors:  J J Schildkraut
Journal:  Annu Rev Med       Date:  1974       Impact factor: 13.739

3.  Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum.

Authors:  H J Gerhards; A Carenzi; E Costa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

4.  8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant.

Authors:  I Hoffmann
Journal:  Arzneimittelforschung       Date:  1973-01

5.  Effect of thymoleptics on fenfluramine-induced depletion of brain serotonin in rats.

Authors:  D Ghezzi; R Samanin; S Bernasconi; G Tognoni; M Gerna; S Garattini
Journal:  Eur J Pharmacol       Date:  1973-11       Impact factor: 4.432

6.  Nomifensine: a potent dopaminergic agonist of antiparkinson potential.

Authors:  B Costall; D M Kelly; R J Naylor
Journal:  Psychopharmacologia       Date:  1975

7.  Pharmacological and biochemical studies with three metabolites of nomifensine.

Authors:  H Kruse; I Hoffmann; H J Gerhards; M Leven; U Schacht
Journal:  Psychopharmacology (Berl)       Date:  1977-01-31       Impact factor: 4.530

8.  The effect of nomifensine on the depletion of brain serotonin and catecholamines induced respectively by fenfluramine and 6-hydroxydopamine in rats.

Authors:  R Samanin; S Bernasconi; S Garattini
Journal:  Eur J Pharmacol       Date:  1975-12       Impact factor: 4.432

9.  Central monoamine deficiency in depressions: causative of secondary phenomenon?

Authors:  H M van Praag; J Korf
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1975-09

Review 10.  The contribution of drug research to investigating the nature of endogenous depression.

Authors:  A Carlsson
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1976-01
View more
  6 in total

1.  Relationship between sensorimotor neglect and the specificity, degree and locus of mesotelencephalic dopaminergic cell loss following 6-hydroxydopamine.

Authors:  G J Lees; R R Kydd; J J Wright
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Nomifensine: effect in Parkinsonian patients not receiving levodopa.

Authors:  D M Park; L J Findley; G Hanks; M Sandler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-04       Impact factor: 10.154

3.  Inhibition of potassium-stimulated release of [3H]dopamine from rat striata as a result of prior exposure to cocaine, nomifensine, or mazindol.

Authors:  D Dembiec
Journal:  Neurochem Res       Date:  1980-03       Impact factor: 3.996

4.  Interaction of alcohol with maprotiline or nomifensine: echocardiographic and psychometric effects.

Authors:  C Strömberg; A Suokas; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  A comparison of the pharmacodynamic profiles of nomifensine and amitriptyline in normal subjects.

Authors:  M Y Chan; R Ehsanullah; J Wadsworth; J McEwen
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

6.  Attenuated response to nomifensine in rats during a swim test following lesion of the habenula complex.

Authors:  E W Thornton; J A Evans; C Harris
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.